Search clinical trials for: Y-90 microspheres

Total 1191 results

Thomas Jefferson University
National Cancer Institute (NCI); National Institutes of Health (NIH)

Active, not recruiting

Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer

Hepatocellular Carcinoma

United States
Methodist Health System

Recruiting

Evaluating the Effects of Selective Treatment Utilizing Flex-dosing for Unresectable HCC With Y90 SIR-Spheres

Hepatocellular Carcinoma

United States
Emory University
National Cancer Institute (NCI); Sirtex Medical

Withdrawn

Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Breast Carcinoma | Metastatic Carcinoma in the Liver

United States
GrandPharma (China) Co., Ltd.

Not yet recruiting

Observational Study for SIR-Spheres Therapy for the Treatment of Unresectable Metastatic Liver Tumors From Primary Colorectal Cancer

Colorectal Neoplasms

China
M.D. Anderson Cancer Center
Sirtex Medical

Recruiting

Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases

Metastases

United States
Sirtex Medical
Bright Research Partners

Recruiting

Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients (DOORwaY90)

Unresectable Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | BCLC Stage A Hepatocellular Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
BTG International Inc.

Completed

Study Of Intrahepatic Arterial Injection of 90-Y Glass Microspheres for Cholangiocarcinoma

Cholangiocarcinoma

United States
Northwestern University
National Cancer Institute (NCI)

Completed

Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Liver Cancer

United States
Allan Tsung

Withdrawn

Radiolabeled Glass Beads (TheraSphere®) in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery

Liver Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma...

United States
City of Hope Medical Center

No longer available

Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Liver Cancer

United States
Northwestern University
National Cancer Institute (NCI)

Completed

Radiolabeled Glass Beads in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery

Metastatic Cancer | Liver Cancer

United States
Southwestern Regional Medical Center

Completed

Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors

Carcinoma, Hepatocellular | Liver Neoplasms

United States
Boston Scientific Corporation

Recruiting

A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM (FRONTIER)

Glioblastoma Multiforme | Recurrent Glioblastoma

United States
Leo W. Jenkins Cancer Center

No longer available

Therasphere® for Treatment of Unresectable Primary Liver Cancer and Metastatic Liver Cancer

Neoplasm Metastasis | Carcinoma, Hepatocellular

United States
Sirtex Medical

Completed

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer (SIRFLOX)

Colorectal Cancer | Liver Metastases | Colorectal Carcinoma

United States, Israel, Australia, Belgium, New Zealand, Spain, Germany, Switzerland, Italy, France, Poland
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Internal Radiation Therapy in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery

Liver Cancer

United States
Goshen Health System

Unknown

Internal Radiation Therapy With Y-90 Microspheres, External Radiation Therapy With Tomotherapy, and Fluorouracil in Treating Patients With Newly Diagnosed or Recurrent Pancreatic Cancer and Liver Metastases That Cannot Be Removed By Surgery

Pancreatic Cancer | Metastatic Cancer

United States
University of Pittsburgh
National Cancer Institute (NCI)

Completed

Hepatic Arterial Chemoembolization With Cisplatin or Internal Radiation Therapy in Treating Patients With Advanced Liver Cancer That Cannot Be Removed By Surgery

Liver Cancer

United States
OHSU Knight Cancer Institute
Oregon Health and Science University; American Society of Clinical Oncology; Radiological... and other collaborators

Withdrawn

Y-90 Versus SBRT for Inoperable HCC

Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma AJCC v8 | Stage IB Hepatocellular Carcinoma AJCC v8 | Stage II Hepatocellular Carcinoma AJCC v8 | Stage... and other conditions

United States
Ohio State University Comprehensive Cancer Center

Completed

Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States
SCRI Development Innovations, LLC
Ipsen

Terminated

Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres

Gastrointestinal Neoplasms | Neuroendocrine Tumors | Carcinoid Tumors

United States
Zhongda Hospital

Recruiting

Yttrium-90 Carbon Microspheres in Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma

China
Chengdu New Radiomedicine Technology Co. LTD.

Recruiting

Safety and Efficacy of NRT6003 in Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D)

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma...

United States
Massachusetts General Hospital
National Institutes of Health (NIH); Implant Sciences

Terminated

Intra-Operative Dural Brachytherapy With Yttrium-90 Plaque Applicators

Spinal Neoplasms

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors

Head and Neck Cancer | Metastatic Cancer | Pheochromocytoma | Islet Cell Tumor

United States
Nicholas Fidelman, MD
Merck Sharp & Dohme LLC; BTG International Inc.

Active, not recruiting

Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases

Neuroendocrine Neoplasm | Metastatic Malignant Neoplasm in the Liver

United States
OHSU Knight Cancer Institute
Oregon Health and Science University; Boston Scientific Corporation

Completed

Radiolabeled Glass Beads Used for Treating Patients With Primary Liver Cancer When Surgery is Not an Option (Y-90HDE)

Liver Cancer | Hepatoma
Seoul National University Hospital

Recruiting

Radiation Major Hepatectomy to Selectively Treat Large Unifocal Hepatocellular Carcinoma (RESCUE)

Hepatocellular Carcinoma

Korea, Republic of
Boston Scientific Corporation

Suspended

First In Human Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device (VOYAGER)

Cancer | Prostate

United States
University of Southern California
National Cancer Institute (NCI)

Withdrawn

Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization

Hepatocellular Carcinoma

United States
Northwestern University
BTG International Inc.

Active, not recruiting

Yttrium-90 Radioembolization for Cirrhosis-Associated Thrombocytopenia

Thrombocytopenia | Cirrhosis

United States
University of Zurich

Withdrawn

Response of Hepatic Tumors to Radioembolization (RESRAD)

Hepatocellular Carcinoma | Intrahepatic Cholangiocarcinoma | Liver Metastasis

Switzerland
Mayo Clinic

Active, not recruiting

Contrast-Enhanced Ultrasound and Shear Wave Elastography for the Treatment of Lymphedema (CASTLE)

Lymphedema Arm

United States
Spectrum Pharmaceuticals, Inc
Bayer

Completed

Zevalin Post-marketing Surveillance in Japan (ZEVALIN-DUI)

Non-Hodgkin's Lymphoma (NHL)

Japan
Bayer

Completed

A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin

Lymphoma, Follicular | Non-Hodgkin Lymphoma

Belgium
Tony Reid, M.D., Ph.D.
Sirtex Medical

Terminated

A Study of Yttrium-90 Radioactive Resin Microspheres to Treat Colorectal Adenocarcinoma Metastatic to the Liver

Liver Neoplasms | Colorectal Neoplasms

United States
Boston Scientific Corporation
BTG International Inc.

Completed

TheraSphere for the Treatment of Liver Metastases

Neoplasm Metastasis | Colorectal Cancer | Carcinoma, Neuroendocrine

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Completed

Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Study (RESiN)

Localized Non-Resectable Adult Liver Carcinoma

United States
Wake Forest University Health Sciences

Completed

HDE Use Protocol of TheraSphere for Treatment of Unresectable HCC

Hepatocellular Carcinoma
European Institute of Oncology
Agenzia Italiana del Farmaco

Recruiting

Neoadjuvant PRRT With Y-90-DOTATOC in pNET (NeoNet)

Pancreatic Neuroendocrine Tumor

Italy
University of Michigan Rogel Cancer Center
Department of Health and Human Services; National Institute for Biomedical...

Recruiting

Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.

Liver Malignancy

United States
University Hospital Southampton NHS Foundation...
Royal Free and University College Medical School

Completed

Targeted Radiotherapy in HSCT for Poor Risk Haematological Malignancy

Lymphoma | Myeloma | Acute Leukaemia | Chronic Leukaemia

United Kingdom
Eastern Hepatobiliary Surgery Hospital

Completed

Radioembolization With Yittrium-90 for Intermediate and Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma | Radioembolization

China
Ondokuz Mayıs University

Not yet recruiting

The Effect of Hope Placement Program on Dıagnosed Wıth MS

Multiple Sclerosis

Turkey
Boston Scientific Corporation
Biocompatibles UK Ltd

Active, not recruiting

Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC) (PROACTIF)

Hepatocellular Carcinoma

France
Yale University

Completed

Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors

Liver Neoplasms

United States
Northwestern University
Bristol-Myers Squibb; National Cancer Institute (NCI)

Terminated

Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection

Hepatocellular Carcinoma

United States
Cardiovascular and Interventional Radiological...

Completed

CIRSE Registry for SIR-Spheres Therapy (CIRT)

Liver Carcinoma

Austria

Search clinical trials for: Y-90 microspheres

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations